跳至主要内容
临床试验/NCT00299975
NCT00299975已完成2 期

A Randomized Controlled Trial of Chinese Herbal Medicine in Three-dose Regimen for the Treatment of Functional Constipation

Hong Kong Baptist University1 个研究点 分布在 1 个国家目标入组 97 人开始时间: 2006年10月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
97
试验地点
1
主要终点
Responder for Complete Spontaneous Bowel Movement (CSBM)

研究概览

简要总结

Functional constipation (FC) is common with 14.3% estimated prevalence in Hong Kong, but treatment for this condition in conventional medicine is suboptimal. Complementary and alternative medicines, especially Chinese herbal medicine (CHM) are used frequently by patients with FC, but there is little research evidence about these commonly used CHM. The purpose of the study is evaluate the efficacy and safety of CHM, as well as determining the optimal dosage.

详细描述

Functional constipation (FC) is a common complaint in clinical practice, with the estimated prevalence 14.3% in Hong Kong, as nearly affecting 1 million Hong Kong People in different extent. It is comparable with western population, which is 15% in North America. By the definition of Rome II criteria, FC comprises a group of functional disorders, which presents as persistent difficult, infrequent or seemingly incomplete defecation.

Constipation is often perceived to be benign, easily treated condition with short-term treatment being relatively straightforward. However, the fact is the management of FC is perplexed as some subjects complain of constipation more than decade. Moreover, chronic constipation can develop into more serious bowel complaints, such as faecal impaction, incontinence and bowel perforations. There is also accumulating evidence shown that constipated subjects have significantly higher anxiety and depression scores and lower quality of life. Therefore, the demand of effective agents to normalize bowel function is extremely large.

Conventional treatment for constipation mainly relies on dietary fibre and laxatives. Although there is no credible evidence that any serious problem is associated with their prolonged use, the treatment of it has been suboptimal. First, a recent systematic review pointed out that there were paucity of trials for many commonly used agents, therefore, their use might not be well validated. Second, many patients with severe constipation do not respond adequately or lose of effectiveness after a short period of time. Third, many patients who intake dietary fibre complain of flatulence, distension, bloating and poor taste. As a result, the compliance is low as about 50%. Fourth, the use of osmotic laxatives, such as polyethylene glycol, become increasingly popular due to fewer side effects and better taste, however, the prices are much more expensive than other medications. Many constipation sufferers seek help from alternative medicine, especially from Chinese herbal medicine. For example, according to a telephone survey in Hong Kong, more than 85% of constipated subjects seek for coping strategies, such as asking for medical consultations, taking prescribed medicine and seeking for alternative therapy, involving Chinese medicine.

Traditional Chinese medicine (TCM) is particularly attractive as their effectiveness in treating functional disorders and retaining balance of body functions. The CHM used in study is derived from classic text of Chinese medicine (Shang Han Lun, Discussion of Cold-induced Disorders), which can "moisten the intestines, drain heat, promote the movement of qi and unblock the bowel".

It is well known that randomized controlled trial (RCT) is the gold standard to test the efficacy of intervention, thus in this project, we attempt to follow the basic requirements of RCT to testify the efficacy and safety of CHM on FC, as well as to determine the optimal dosage. We believe such study will benefit the advancement of CHM, or even as the foundation of research study in future.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Clinical diagnosis of functional constipation with Rome II criteria
  • General stool type belongs to Type 1 to 4 according to Bristol Stool Form Scale
  • Complete spontaneous bowel movement≦2 movements per week

排除标准

  • Anti-diarrhoeal therapy
  • Drug-induced constipation
  • Medical history of important bowel pathology, such as inflammatory bowel disease, congenital or acquired megacolon / megarectum
  • Medical history of previous abdominal surgery
  • Taking chronic medications that contain any kind of herbs, mineral, or specific vitamin supplements
  • Medical history of carbohydrate malabsorption, hormonal disorder, cancer, diabetes mellitus, hypothyroidism, asthma, renal impairment and/or any other serious diseases
  • History of laxative abuse
  • History of allergy to Chinese herbal medicine
  • Psychiatric or addictive disorders
  • Pregnancy or breast-feeding
  • Any other serious diseases

研究组 & 干预措施

MaZiRenWan (MZRW) Low dose

Experimental

MaZiRenWan (MZRW) Low dose 2.5g sachet by mouth, twice daily for 8 weeks

干预措施: MaZiRenWan (MZRW) Low dose (Drug)

MaZiRenWan (MZRW) Median dose

Experimental

MaZiRenWan (MZRW) Median dose 5.0g sachet by mouth, twice daily for 8 weeks

干预措施: MaZiRenWan (MZRW) Median dose (Drug)

MaZiRenWan (MZRW) High dose

Experimental

MaZiRenWan (MZRW) High dose 7.5g sachet by mouth, twice daily for 8 weeks

干预措施: MaZiRenWan (MZRW) High dose (Drug)

结局指标

主要结局

Responder for Complete Spontaneous Bowel Movement (CSBM)

时间窗: Week3-10

Participants with a mean increase of CSBM\>=1 movement per week compared with the last 14 days of the run-in period were defined as responders.CSBM referred to the feeling that defecation led to complete passage of stool rather than partial or incomplete evacuation without the use of any laxative or enema within 24 hours.

次要结局

  • Responder for Complete Spontaneous Bowel Movement (CSBM)(Week11-18)
  • Bowel Movement(Baseline(Week1-2), Within treatment(Week3-10) & Within follow-up(Week11-18))
  • Global Symptoms Improvement(Week6, 10 & 18)
  • Sensation of Straining(Baseline(Week2), Within treatment(Week6), End of treatment(Week10) & End of follow-up(Week18))
  • Blood Urea Level(Pre-treatment(Week2) & Post-treatment(Week10))
  • Complete Spontaneous Bowel Movement (CSBM)(Baseline(Week1-2), Within treatment(Week3-10) & Within follow-up(Week11-18))
  • Severity of Constipation(Baseline(Week2), Within treatment(Week6), End of treatment(Week10) & End of follow-up(Week18))
  • Incomplete of Evacuation(Baseline(Week2), Within treatment(Week6), End of treatment(Week10) & End of follow-up(Week18))
  • Sensation of Bloating(Baseline(Week2), Within treatment(Week6), End of treatment(Week10) & End of follow-up(Week18))
  • Sensation of Abdominal Pain/Cramping(Baseline(Week2), Within treatment(Week6), End of treatment(Week10) & End of follow-up(Week18))
  • Blood Creatinine Level(Pre-treatment(Week2) & Post-treatment(Week10))
  • Serum Glutamic Pyruvic Transaminase(SGPT) Level(Pre-treatment(Week2) & Post-treatment(Week10))
  • Passing of Gas(Baseline(Week2), Within treatment(Week6), End of treatment(Week10) & End of follow-up(Week18))
  • Adverse Effects (e.g. Renal and Liver Function Tests)(pre-treatment & post-treatment)
  • Serum Glutamic Oxaloacetic Transaminase(SGOT) Level(Pre-treatment(Week2) & Post-treatment(Week10))

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

ZhaoXiang Bian

Professor, Director of Clinical Division

Hong Kong Baptist University

研究点 (1)

Loading locations...

相似试验